Developmental aspects of drug metabolism in children

Drug Information Journal

Volumn 30, Issue 4, 1996, Pages 1135-1143

  Leeder, J Steven ^a,b  

^a HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^b CHILDREN S MERCY HOSPITAL   (United States)

Author keywords

Cytochrome P450; Development; Drug metabolism; Ontogeny

Indexed keywords

ANTINEOPLASTIC AGENT; CARBAMAZEPINE; CARBAMAZEPINE 10,11 OXIDE; CYCLOSPORIN; CYTOCHROME P450; DEBRISOQUINE; DEXTROMETHORPHAN; DRUG METABOLIZING ENZYME; PHENOBARBITAL; PHENYTOIN; THEOPHYLLINE;

CHILD; CHILD DEVELOPMENT; DEMETHYLATION; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG TRANSFORMATION; ENZYME INDUCTION; GRAFT REJECTION; HUMAN; INFANT; NEWBORN; ONTOGENY; PHENOTYPE; PRIORITY JOURNAL; REVIEW; TREATMENT FAILURE;

EID: 0029828785     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/009286159603000432     Document Type: Review

References (38)

1. Nelson DR, Kamataki T, Waxman DJ, et al. The P450 superfamily: Update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA Cell Biol. 1993; 12:1-51.
2. Wrighton, SA, Stevens JC. The human hepatic cytochromes P450 involved in drug metabolism. CRC Crit Rev Toxicol. 1992;22:1-21.
3. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther. 1994;270:414-423.
4. Forrester LM, Henderson CJ, Glancy MJ, et al. Relative expression of cytochrome P450 isoenzymes in human liver and association with the metabolism of drugs and xenobiotics. Biocehm J. 1992;281:359-368.
5. Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena Jr. LR. Changes in the pharmacokinetics and electrocardiographic pharmacodynamics in terfenadine with concomitant administration of erythromycin. Clin Pharmacol Ther. 1992;52:231-238.
6. Bailey DG, Arnold JMO, Spence JD. Grapefruit juice and drugs: how significant is the interaction? Clin Pharmacokin. 1994;26:91-98.
7. Renton KW, Knickle LC. Regulation of cytochrome P-450 during infectious disease. Can J Pharmacol Physiol. 1990;68:777-781.
8. Kraus DM, Fischer JH, Reitz SJ, et al. Alterations in theophylline metabolism during the first year of life. Clin Pharmacol Ther. 1993;54:351-359.
9. Weiss CF, Glazko AJ, Weston JK. Chloramphenicol in the newborn infant. A physiologic explanation of its toxicity when given in excessive doses. New Engl J Med. 1960;262:787-794.
10. Young III WS, Lietman PS. Chloramphenicol glucuronyl transferase: assay, ontogeny and inducibility. J Pharmacol Exp Ther. 1978;204:203-211.
11. Miller RP, Roberts RJ, Fischer LJ. Acetaminophen elimination kinetics in neonates, children, and adults. Clin Pharmacol Ther. 1976;19:284-294.
12. Hakkola J, Pasanen M, Purkunen R, et al. Expression of xenobiotic-metabolizing cytochrome P450 forms in human adult and fetal liver. Biochem Pharmacol. 1994;48:59-64.
13. Yang H-Y, L, Namkung MJ, Juchau MR. Expression of functional cytochrome P4501A1 in human embryonic hepatic tissues during organogenesis. Biochem Pharmacol. 1995;49:717-726.
14. Cazeneave C, Pons G, Rey E, et al. Biotransformation of caffeine in human liver microsomes from foetuses, neonates, infants and adults. Br J Clin Pharmacol. 1994;37:405-412.
15. Zhang Z-Y, Kaminsky LS. Characterization of human cytochromes P450 involved in theophylline 8-hydroxylation. Biochem Pharmacol. 1995;50:205-211.
16. Nassif EG, Weinberger MM, Shannon D, et al. Theophylline disposition in infancy. J Pediatr. 1981; 98:158-161.
17. Milavetz G, Vaughan LM, Weinberger MM, Hendeles L. Evaluation of a scheme for establishing and maintaining dosage of theophylline in ambulatory patients with chronic asthma. J Pediatr. 1986; 109:351-354.
18. Lambert GH, Schoeller DA, Kotake AN, Flores C, Hay D. The effect of age, gender, and sexual maturation on the caffeine breath test. Dev Pharmacol Ther. 1986;9:375-388.
19. Meyer U, Skoda RC, Zanger UM, Heim M, Broly F. The genetic polymorphism of debrisoquine/sparteine metabolism - molecular mechanisms. In: Kalow W, ed. Pharmacogenetics of Drug Metabolism. New York: Pergamon Press; 1992:609-623.
20. Eichelbaum M, Gross AS. The genetic polymorphism of debrisoquine/sparteine metabolism - clinical aspects. Pharmacol Ther. 1990;46:377-394.
21. Schmid B, Bircher J, Presig R, Küpfer A. Polymorphic dextromethorphan metabolism: Co-segregation of oxidative O-demethylation with debrisoquine hydroxylation. Clin Pharmacol Ther. 1985;38:618-624.
22. 1 activity. Clin Pharmacol Ther. 1989;45:34-40.
23. Ladona MG, Lindström B, Thry C, Dun-Ren P, Rane A. Differential fetal development of the O- and N-demethylation of codeine and dextromethorphan in man. Br J Clin Pharmacol. 1991;32:295-302.
24. Treluyer J-M, Jacqz-Aigran E, Alvarez F, Cresteil T. Expression of CYP2D6 in developing human liver. Eur J Biochem. 1991;202:583-588.
25. Relling MV, Cherrie J, Schell MJ, Petros WP, Meyer WH, Evans WE. Lower prevalence of the debrisoquin oxidative poor metabolizer phenotype in American black versus white subjects. Clin Pharmacol Ther. 1991;50:308-313.
26. Wrighton SA, Ring BJ, Watkins PB, Vandenbranden M. Identification of a polymorphically expressed member of the human cytochrome P-450III family. Mol Pharmacol. 1989;36:97-105.
27. Wrighton SA, VandenBranden M. Isolation and characterization of human fetal liver cytochrome P450HLp2: a third member of the P450III gene family. Arch Biochem Biophys. 1989;268:144-151.
28. Schuetz JD, Beach DL, Guzelian PS. Selective expression of cytochrome P450 CYP3A mRNAs in embryonic and adult human liver. Pharmacogenetics. 1994;4:11-20.
29. Watkins PB. Noninvasive tests of CYP3A enzymes. Pharmacogenetics. 1994;4:171-184.
30. Yang H-YL, Lee QP, Rettie AR, Juchau MR. Functional cytochrome P4503A isoforms in human embryonic tissues: Expression during organogenesis. Mol Pharmacol. 1994;46:922-928.
31. Jacqz-Aigrain E, Cresteil T. Cytochrome P450-dependent metabolism of dextromethorphan: fetal and adult studies. Dev Pharmacol Ther. 1992;18:161-168.
32. Schuetz EG, Schuetz JD, Grogan WM, et al. Expression of cytochrome P450 3A in amphibian, rat and human kidney. Arch Biochem Biophys. 1992;294: 206-214.
33. Kolars JC, Lown KC, Schmiedlin-Ren P, et al. CYP3A gene expression in human gut epithelium. Pharmacogenetics. 1994;4:247-259.
34. Kerr BM, Thummel KE, Wurden CJ, et al. Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation. Biochem Pharmacol. 1994;47:1969-1979.
35. Korinthenberg R, Haug C, Hannak D. The metabolization of carbamazepine to CBZ-10,11-epoxide in children from the newborn age to adolescence. Neuropediatrics. 1994;25:214-216.
36. Watkins PB, Wrighton SA, Maurel P, et al. Identification of an inducible form of cytochrome P-450 in human liver. Proc Natl Acad Sci USA. 1985;82: 6310-6314.
37. Rane A, Höjer B, Wilson JT. Kinetics of carbamazepine and its 10,11-epoxide metabolite in children. Clin Pharmacol Ther. 1976;19:276-273.
38. Furlanut M, Montanari G, Bonin P, Casara GL. Carbamazepine and carbamazepine-10,11-epoxide serum concentrations in epileptic children. J Pediatr. 1985;106:491-495.